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Abstract
Background: Chronic obstructive pulmonary disease (COPD) is characterized by both airway remodeling and parenchymal
destruction. The identification of unique biomarker patterns associated with airway dominant versus parenchymal
dominant patterns would support the existence of unique phenotypes representing independent biologic processes. A
cross-sectional study was performed to examine the association of serum biomarkers with radiographic airway and
parenchymal phenotypes of COPD.
Methodology/Principal Findings: Serum from 234 subjects enrolled in a CT screening cohort was analyzed for 33 cytokines
and growth factors using a multiplex protein array. The association of serum markers with forced expiratory volume in one
second percent predicted (FEV1%) and quantitative CT measurements of airway thickening and emphysema was assessed
with and without stratification for current smoking status. Significant associations were found with several serum
inflammatory proteins and measurements of FEV1%, airway thickening, and parenchymal emphysema independent of
smoking status. The association of select analytes with airway thickening and emphysema was independent of FEV1%.
Furthermore, the relationship between other inflammatory markers and measurements of physiologic obstruction or airway
thickening was dependent on current smoking status.
Conclusions/Significance: Airway and parenchymal phenotypes of COPD are associated with unique systemic serum
biomarker profiles. Serum biomarker patterns may provide a more precise classification of the COPD syndrome, provide
insights into disease pathogenesis and identify targets for novel patient-specific biological therapies.
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Introduction
While airflow obstruction is the hallmark of chronic obstructive
pulmonary disease (COPD), the distinct processes of parenchymal
destruction and small airway fibrosis can induce similar impair-
ments in expiratory flow. Varying contributions of airway
remodeling and emphysema can be found in any individual,
leading to significant heterogeneity in disease expression [1,2,3,4].
The precise classification of these disease phenotypes is paramount
to the elucidation of pathogenic mechanisms and the development
of innovative, effective therapies for COPD. In fact, future
research efforts will be immobilized without a more thorough
understanding of the molecular pathogenesis driving phenotype
expression and a more refined schema for characterizing disease.
Although the presence of systemic inflammation in COPD is
widely accepted [4,5,6,7], the inter-individual variation in the
patterns of the inflammatory response is not emphasized in the
existing literature. The diverse presentation of disease resulting
from a single environmental exposure, cigarette smoke, suggests
the presence of distinct bio-molecular and cellular pathways
leading to a divergence of anatomic phenotypes. However, the
variation of peripheral inflammatory mediators and the associa-
PLoS ONE | www.plosone.org 1 August 2009 | Volume 4 | Issue 8 | e6865tion with pulmonary histopathologic phenotypes remains a largely
uninvestigated research area. Whereas the recent evolution of
quantitative computed tomography (CT) technology has provided
a non-invasive method of estimating the contribution of airway
thickening versus parenchymal emphysema within an individual
patient [2,8,9,10,11], we postulated that characterization of the
inflammatory profile within radiographic sub-types of COPD will
provide a basis for the refinement of disease classification, offer
insights into variations in disease pathogenesis and identify novel
therapeutic targets and surrogates associated with clinically
meaningful outcomes. Therefore, we conducted a cross-sectional
study examining both the association of unique serum inflamma-
tory profiles with quantitative CT derived airway and parenchy-
mal phenotypes of COPD and the variation of these associations
with smoking status.
Methods
The following is an abridged version of the methods section.
Please refer to Methods S1 for detailed methodology.
Ethics Statement
The study protocol was approved by the University of
Pittsburgh Institutional Review Board. Participating subjects
provided written informed consent for research use of their CT
scans and blood samples.
Subject Selection
Two hundred and thirty-four participants were selected from
the Pittsburgh Lung Screening Study (PLuSS) cohort. Participants
were current or former smokers ages 50–79 and were selected to
represent the spectrum of visual radiographic emphysema and
airflow obstruction (Table S1, Table S2, Table S3). Subjects with a
restrictive spirometric pattern, history of lung cancer, or suspicion
of lung cancer at screening were excluded from the study. All
subjects were ambulatory and self-referred from a mass-mailing
recruitment effort.
Pulmonary Function Testing
Spirometry was performed on all subjects upon entry into the
PLuSS cohort. Testing was performed using standard methodol-
ogy [12,13] and reference equations [14].
Quantitative CT Analysis
The subjects underwent low-dose CT examinations performed
on either a LightSpeed Plus 4-detector (n=110) or LightSpeed
Ultra 8-detector (n=124) (GE Healthcare). The CT examinations
were acquired using a helical technique at 120 or 140 kVp with a
mean tube current-time product of 28.9 (+7.9) mAs. Images were
reconstructed contiguously at 2.5 mm section thickness with a
2.5 mm interval using a GE Healthcare high-spatial frequency
kernel with a range of pixel dimensions from 0.54 to 0.98 mm.
The apical bronchus of the right upper lobe was manually
selected from the CT images and analyzed in cross-section. Wall
area as a percentage of total airway area (WA%), which has been
associated with lung function [15,16], was computed using a
partial membership algorithm developed at the University of
Pittsburgh [17,18] and used as a measure of bronchial thickening.
The lung depicted in CT images was segmented [19] and the
extent of emphysema was assessed using the density-mask
technique [9]. Parenchymal voxels with computed attenuation
values less than 2950 Hounsfield Units (HU) were defined to be
associated with emphysema. The volume of lung associated with
emphysema was represented as the fraction voxels less than the
2950 HU threshold of the total computed lung volume (F-950).
Serum biomarker measurements
Stored serum samples were analyzed for thirty-three serum
chemokines and growth factors using a bead-based cytometric
immunoassay system (Luminex, Austin, TX). A detailed description
of the methods of the multiplex assay performed at the Core facility
has been described previously by others [20]. Standard curves were
generated foreach cytokineinconcordance with themanufacturer’s
instructions and the concentrations of unknown samples were
calculated using a 5 parametric curve-fitting program with logistic
regression (Bio-Rad Laboratories, Hercules, CA).
Statistical Analysis
Continuous data were summarized as either mean 6 standard
deviation or median and quartiles and categorical data were
expressed as percentages. The association between the forced
expiratory volume in the first second percent predicted (FEV1%)
and WA% and F-950 was analyzed using univariate linear
regression analysis. The contribution of WA% and F-950 to
FEV% was then determined using multiple regression analysis.
Finally, the relationship between WA% and F-950 was assessed
with the Pearson’s correlation coefficient.
Serum biomarkers with concentrations above or below the
detection threshold of the assay were respectively assigned the
highest or lowest extrapolated value for that given marker (Table S4).
Because the data was not normally distributed, biomarker levels were
log-transformed and the association between the log-transformed
values and FEV1%, WA% and F-950 for the entire cohort was
assessed using univariate linear regression analysis and multiple
regression analysis after adjusting for smoking status. Linear
regression analysis stratified for smoking status was then performed
to evaluate the association of serum inflammatory markers and
FEV1%, WA% and F-950 separately in current and former smokers.
All statistical procedures were performed using SAS version 9.1.
Results
Subject demographics
The selected cohort consisted of 149 current and 85 former
smokers (Table 1). The subjects’ FEV1% ranged from 15 to 134%
with a mean of 68.2% (627.1%). The mean subject age was 61.3
years with a range of 50 to 78 years.
Table 1. Subject Characteristics by GOLD Classification.
Characteristics GOLD Category
At Risk 1 2 3 4
(n=56) (n=38) (n=58) (n=64) (n=18)
Age 59.167.2 62.168.0 61.767.2 62.567.1 60.666.5
Sex
Male 25 (45%) 22 (58%) 29 (50%) 33 (52%) 7 (39%)
Female 31 (55%) 16 (42%) 29 (50%) 31 (48%) 11 (61%)
Current Smoker 30 (54%) 27 (71%) 43 (74%) 41 (64%) 8 (44%)
FEV1 (%) 98.4613.0 92.168.4 67.268.0 40.965.9 23.864.8
FEV1/FVC (%) 76.964.5 63.564.3 59.667.5 44.267.3 32.766.5
doi:10.1371/journal.pone.0006865.t001
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Both WA% and F-950 were correlated with FEV1% in univariate
analysis (r=20.39, p=,0.0001; r=20.43, p=,0.0001) and each
CT parameter independently contributed to FEV1 decline in
multivariate analysis (r=0.6). Although there was a strong association
of airway thickening and parenchymal emphysema CT phenotypes
with FEV1%, there was no association of the CT phenotypes to each
other (r=20.055, p=0.40) suggesting that each parameter repre-
sents an independent, unique phenotype (Fig. 1).
Association between serum inflammatory markers and
FEV1%
Four of the 33 markers were modestly associated with FEV1%
(p=,0.05) before and after adjustment for current smoking status
(Table 2). Eotaxin, matrix metalloproteinase (MMP)-1, and MMP-
7 were inversely associated with FEV1%. Epidermal growth factor
receptor (EGFR) showed a direct association with FEV1% and
thus decreased with increasing GOLD classification.
Association between serum inflammatory markers and
WA%
Seven of the 33 biomarkers were associated with WA%.
Interleukin (IL) -6, IL-13, IL-2 receptor, Interferon gamma (IFN-
c), and c-reactive protein (CRP) were directly associated with
WA% while regulated on activation normal T cell expressed and
secreted (RANTES) was inversely associated with this CT
parameter (Table 3, Table S5). Notably none of these markers
demonstrated independent association with FEV1. On the other
hand, consistent with its direct relationship with FEV1%, EGFR
decreased as WA% increased. All relationships held with
adjustment for current smoking status. Notably, none of the
above markers, except IL-6, demonstrated an association with F-
950 despite their association with airway wall thickness.
Association between serum inflammatory markers and
F-950
Three of the 33 inflammatory markers, IL-6, MMP-7 and tumor
necrosis factor alpha (TNF-a), were associated with quantitative
emphysema (Table 4, Table S5). While IL-6 and MMP-7 were
directly associated with F-950, TNF-a was inversely related to
emphysema severity. Again, adjustment for smoking status had little
effect on the association of biomarkers and emphysema. Of note,
MMP-7 showed consistent associations across both FEV1% and F-
950, demonstrating an inverse relationship with FEV1% and a
direct relationship with F-950 but not WA%.
Figure 1. Scatter plot of the fraction of CT voxels with attenuation values less than 2950 Hounsfield Units (F-950) plotted on the X-
axis and the right upper apical lobe bronchus wall area as a percentage of total airway area (WA%) plotted on the Y-axis. Tertiles of
F-950 and WA% are demarcated by the dotted vertical and horizontal lines within the scatter plot with the mean FEV1 percent predicted (FEV1%)
values represented in the corresponding color-coded grid. No association exists between F-950 and WA% (r=20.055, p=0.40) and the severity of
parenchymal emphysema and airway disease cannot be predicted based on FEV1 alone.
doi:10.1371/journal.pone.0006865.g001
Table 2. Association Between Log Transformed Serum
Markers and FEV1 Percent Predicted (N=234).
Analyte Co-Efficient (log pg/ml / % predicted) P-Value
Eotaxin 217.09 0.04
MMP-1 28.55 0.02
MMP-7 218.19 0.02
EGFR 42.16 0.05
doi:10.1371/journal.pone.0006865.t002
Table 3. Association Between Log Transformed Serum
Markers and Percent Wall Area (N=234).
Analyte Co-Efficient (log pg/ml / WA%) P-Value
IL-2R 3.17 0.003
IL-6 1.58 0.01
IL-13 4.68 0.009
IFN-c 3.03 0.01
EGFR 212.65 0.04
RANTES 21.76 0.05
CRP 2.36 0.03
doi:10.1371/journal.pone.0006865.t003
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Stratified analysis by smoking status revealed a relationship
between specific biomarkers and FEV1% (Table 5) that differs
based on smoking status. The association of eotaxin, EGFR,
MMP-1, and MMP-7 with obstruction was significant in former,
but not current, smokers.
Likewise, the relationship between serum biomarkers and WA%
in current versus former smokers demonstrated associations
dependent on current smoking status (Table 6). While IL-13
concentrations were directly associated with WA% (Table 3) and
increased with increasing WA% tertiles (Fig. 2), these relationships
were only observed in current smokers (Table 6; Fig. 3). Similarly,
a significant association of IL-6, IFN-c, and CRP with WA% was
present only in current smokers (Table 6). This is in contrast to
serum EGFR concentrations, which were directly associated with
FEV1 (Table 5) and showed a trend toward decreasing with
increasing GOLD classification in former, but not current,
smokers (Fig. 4). MMP-2, MMP-7 and TNF-a receptor two
(TNF-RII) were also significantly associated with WA% in ex-
smokers alone. Notably, subjects’ smoking status did not affect the
associations between serum inflammatory markers and quantita-
tive emphysema.
Discussion
Recently, the paradigm has shifted away from viewing COPD
as a single disease entity to viewing it as a heterogeneous syndrome
with variable contributions of peripheral airway fibrosis and
emphysema. Our study illustrates this heterogeneity in a cohort of
high-risk smokers and demonstrates systemic inflammatory
patterns distinctive to individual anatomic phenotypes. Although
the presence of a generalized systemic inflammatory response in
individuals with both stable and progressive COPD has been well
established [4,5,6,7], only recently have studies explored the
relationship between inflammatory biomarkers and distinct disease
phenotypes. Elevation of select biomarkers have been implicated
in COPD patients with increased resting energy expenditures [21]
and skeletal muscle loss [22]. Blood markers or genetic
polymorphisms have been shown to vary independently with
functional capacity, severity of dyspnea, diffusing capacity, and
BODE score [23,24,25]. To our knowledge, no study has explored
the variation of serum inflammatory markers in association with
CT indices of emphysema and airway disease.
The severity of airway remodeling and parenchymal emphyse-
ma can be characterized with quantitative CT analysis. Histolog-
ical-radiological correlate studies have demonstrated a relationship
between the extent of low attenuation areas depicted on CT
images and histologic emphysema [8,9]. Quantitative CT analysis
of low generation airways have also been shown to correlate with
disease of the small airways [26], the dominant site of airway
Table 4. Association Between Log Transformed Serum
Markers and Percent Emphysema (N=234).
Analyte Co-Efficient (log pg/ml / F-950) P-Value
IL-6 0.016 0.02
TNF-a 20.011 0.04
MMP-7 0.047 0.04
doi:10.1371/journal.pone.0006865.t004
Table 5. Association Between Log Transformed Serum
Markers and FEV1 Percent Predicted Stratified by Current
Smoking Status.
Analyte
Co-Efficient
(log pg/ml / % pred) P-Value
Co-Efficient
(log pg/ml / % pred) P-Value
Former n=85 Current n=149
EGFR 68.07 0.04 19.28 0.49
Eotaxin 232.78 0.02 26.97 0.51
FAS-L 234.53 0.02 4.27 0.64
MMP-1 216.91 0.01 23.95 0.39
MMP-7 229.58 0.009 27.30 0.48
doi:10.1371/journal.pone.0006865.t005
Figure 2. Bar graph representing mean (standard error of the
mean) interleukin 13 (IL-13) serum levels between tertiles of
wall area percentage (WA%) and emphysema (F-950). IL-13
serum levels increase with increasing tertiles of WA% with the highest
levels occurring in those subjects with the most airway thickening
(p=0.038). IL-13 serum levels do not significantly vary between tertiles
of F-950.
doi:10.1371/journal.pone.0006865.g002
Table 6. Association Between Log Transformed Serum
Markers and Wall Area Stratified by Current Smoking Status.
Analyte
Co-Efficient
(log pg/ml / WA%) P-Value
Co-Efficient
(log pg/ml / WA%) P-Value
Former n=85 Current n=149
IL-2R 3.81 0.01 2.69 0.06
IL-6 0.23 0.84 2.16 0.006
IL-13 2.51 0.33 6.46 0.008
IFN-c 1.85 0.28 3.97 0.01
CRP 0.47 0.79 3.47 0.01
EGFR 219.86 0.02 26.24 0.47
TNF-RII 10.14 0.03 0.78 0.82
MMP-2 18.33 0.05 27.94 0.41
MMP-7 8.01 0.006 23.07 0.34
doi:10.1371/journal.pone.0006865.t006
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significant contribution of quantitative CT estimates of airway
remodeling and parenchymal emphysema to FEV1 in smokers
with a wide spectrum of airflow obstruction, supporting the
coexistence of two unique CT phenotypes that correlate with
disease severity and vary remarkably between individuals.
Our findings of distinct inflammatory patterns associated with
airway thickening and parenchymal emphysema supports the
existence of unique biological processes contributing to the
syndrome of COPD. Of the markers demonstrating a significant
association with airway thickening, only EGFR demonstrated an
association with FEV1 and only IL-6 was simultaneously associated
with parenchymal emphysema. Because our study focused on the
measurement of serum biomarkers, we can not know whether the
patterns of peripheralinflammation reflect a ‘‘spill-over’’ of the local
inflammatory milieu within the lungs or represent a synchronous,
systemic molecular diatheses associated with either airway or
parenchymal disease. The significant but modest associations imply
that a complex interplay of chemokines and growth factors, rather
than one or two inflammatory mediators, is associated with the
development of individual phenotypes.
In a complex disease where pathogenic processes progress after
cessation of cigarette smoking [29], we have also demonstrated
inflammatory marker associations with airway remodeling and
obstruction severity that varied according to current smoking
status. Both animal and human studies have shown increased
inflammatory proteins in the presence of cigarette smoke
[30,31,32] and prior groups have found smoking-dependent
differential associations between inflammatory proteins and
markers of disease severity [33]. Relevant to our finding of a
direct association of IFN-c and IL-13 with WA% in current, but
not former, smokers, others have also demonstrated interactions
between smoking and both IFN-c [34] and IL-13 [35]
polymorphisms in association with lung function. We have further
defined specific associations with CT measures of airway
thickening independent of airflow obstruction. This differential
relationship suggests that, while inflammation may persist
following smoking cessation, the specific biological processes may
differ from that in current smokers. Alternatively, underlying
processes associated with either innate [36] or adaptive immune
responses to colonization or autoimmunity[37,38] may be
dominated by the inflammatory effects of tobacco smoke. Such
associations emphasize the complexity of the inflammatory process
underlying the pathophysiology of COPD.
Although the multiple simultaneous measurements enabled by
the high-throughput nature of Luminex technology increases the
probability of type I error, we did not correct for multiple
comparisons in our analysis. A formal adjustment would minimize
the number of false positive findings but would also increase the
probability of missing clinically meaningful associations. In this
exploratory study, we did not want to overlook possible relation-
ships and instead focused on those markers that demonstrated both
biological plausibility and consistency in their associations with CT
parameters.Forinstance,wefoundthatIL-13,acytokineassociated
with lung [39] and airway inflammation and fibrosis [40] in animal
models and lung function in human studies [25,35,41], was directly
related to WA% in our study cohort. Although IL-13 and FEV1%
were not inversely associated in this study, we did find a significant
indirect relationship in a separate cohort of individuals with COPD
[25].EGFR,asoluble growthfactorreceptorwhichhasbeenshown
to be decreased in individuals with breast carcinoma [42], non-
small cell lung carcinoma, and head and neck carcinoma [43] and
to be lower with increased melanoma tumor burden [44], appeared
to havea protective effectin our study cohort – levels increased with
increasing FEV1% and decreasing WA%. The biological plausi-
bility of IL-13 and the consistency across EGFR relationships
suggests clinically meaningful associations that are not merely a
result of increased type-I error. Although the number of plausible
associations we have observed are statistically unlikely to have
occurred randomly, we fully acknowledge that any individual
markers identified must be further validated in other ongoing
patient cohorts [45]. Likewise, as CT technologies evolve enabling
analysis of multiple, higher generation airways, further validation
studies will be necessary to either confirm these molecular
associations or to determine whether analysis of the right upper
Figure 4. Bar graph representing mean (standard error of the
mean) soluble epidermal growth factor receptor (EGFR) serum
levels between GOLD groups stratified by smoking status. EGFR
serum levels decrease with increasing GOLD group in former smokers
(p=0.16) but do not significantly vary with severity of obstruction in
current smokers (FS=former smoker, CS=current smoker).
doi:10.1371/journal.pone.0006865.g004
Figure 3. Bar graph representing mean (standard error of the
mean) interleukin 13 (IL-13) serum levels between tertiles of
wall area percentage (WA%) stratified by smoking status. IL-13
serum levels increase significantly with increasing WA% tertile only in
current smokers (p=0.003). Former smokers do not exhibit a significant
change in IL-13 levels with degree of airway thickening (FS=former
smokers, CS=current smokers).
doi:10.1371/journal.pone.0006865.g003
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meaningful information.
In conclusion, our study illustrates the heterogeneity of the
COPD syndrome exemplified by independent variability of airway
remodeling and parenchymal destruction and demonstrates an
association between distinct quantitative CT phenotypes and serum
inflammatory biomarker patterns. Manyof theseassociationsvaried
according to current cigarette use, suggesting a complex interplay of
inflammation and environment leading to the variable expression of
airway disease and obstruction. The traditional definitionof chronic
airflow obstruction fails to recognize the diversity of biologic
processes represented by varying patterns of disease expression,
which most likely will vary in response to molecular therapeutics.
The challenge is to develop tools that precisely classify individuals
based on their unique pathophysiologic phenotypes. Whereas
quantitative CT indices of emphysema and airway remodeling
have been shown to correlate with physiology and histology, the
identificationofinflammatorymarkers that segregatewithanatomic
phenotypes further validates and facilitates more robust disease sub-
classification and provides further insight into molecular-cellular
mechanisms, potential therapeutic targets and easily measured
surrogates of disease activity.
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